Last reviewed · How we verify

NCT06571370: WaveCRESST

Wave Crossover ECP Study for Simplified Therapy

Completed NA Results posted Last updated 7 April 2026
What this trial tests

NA trial testing External Counterpulsation in Chronic Stable Angina in 52 participants. Completed in 4 February 2025.

Timeline
26 September 2024
Primary endpoint
4 February 2025
4 February 2025

Quick facts

Lead sponsorPression
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment52
Start date26 September 2024
Primary completion4 February 2025
Estimated completion4 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pression — full company profile →

Who can join

35 and older, any sex, with Chronic Stable Angina or Refractory Angina. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Diastolic Augmentation Primary · During treatment, measured at the 8th minute of compressions

The primary effectiveness endpoint was the average Diastolic Augmentation (DA) ratio for the 8th minute of compressions with each ECP device tested for each participant, as identified by the blinded Independent Waveform Evaluator. Diastolic Augmentation (DA) ratio, also referred to as Diastolic/Systolic (D/S) ratio and Effectiveness Ratio (ER), noninvasively characterizes the hemodynamic effect and thus the clinical effectiveness of ECP treatment. DA ratio is a unitless measure which is "calculated as the ratio of the peak diastolic amplitude divided by the peak systolic amplitude" \[Suresh et

GroupValue95% CI
Pression Wave PRO ECP System0.830.77 – 0.88
Predicate ECP Device0.570.52 – 0.62
Systolic Unloading (Mean) Secondary · At last compression after 10 minutes of compression

The level of systolic unloading was recorded based on the systolic peaks during compressions compared to baseline PPG data. Systolic unloading is the percent change of peak systolic amplitude calculated as the difference of the compression waveform - non-compressed baseline waveform divided by amplitude at compression waveform. Systolic unloading components were measured using the peak systolic amplitude on the last compression waveform from the ECP session. The baseline non-compressed peak systolic amplitude was measured from the waveform immediately following the compressed waveform. Higher

GroupValue95% CI
Pression Wave PRO ECP System9.2± 22.8
Systolic Unloading (Categorical) Secondary · At last compression after 10 minutes of compression

Systolic unloading is the ratio of the systolic peak during compressions divided by baseline systolic peak. Systolic unloading is represented by a percentage decrease of systolic peak value with and without compression. This value should be \< 1. The baseline systolic peaks after compressions will be used. Higher levels of systolic unloading are considered better. The predicate devices are documented to produce mean systolic unloading of approximately 11%.

GroupValue95% CI
Pression Wave PRO ECP System27
Pression Wave PRO ECP System20

Sponsor's own description

The purpose of this study is to demonstrate substantial equivalence between Pression's Wave PRO System and a commercially available predicate ECP device to support a U.S. 510(k) submission for the Wave PRO System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of External Counterpulsation

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06571370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing